Christian Stegmann retweeted
Love the question @pmarca. Thick, dark hair regrowth in monkeys and mice👇
ABS-201 human interim efficacy readout expected next year. Hair’s next big moment 🛰️
@elonmusk @davidasinclair @abscibio $absi
Christian Stegmann retweeted
Krise? Welche Krise? handelszeitung.ch/konjunktur…
Christian Stegmann retweeted
IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding @abscibio
1. The first in vitro validation of antibody inverse folding for designing binders to therapeutic antigens. IgDesign achieves high success rates across eight therapeutic targets, marking a breakthrough in computational antibody design.
2. A key innovation: IgDesign generates de novo antibody binders with some designs achieving better affinities than clinically validated reference antibodies. This positions the model as a game-changer for lead optimization and de novo antibody development.
3. IgDesign’s HCDR123 designs show superior binding rates for 7/8 antigens compared to HCDR3-only baselines. This highlights the model’s ability to design complete CDR loops with strong antigen-binding capabilities.
4. The study benchmarks IgDesign’s performance using 1437 antibodies screened via surface plasmon resonance (SPR), identifying 278 binders. This extensive dataset serves as a resource for future antibody design benchmarking.
5. IgDesign leverages deep learning and inverse folding to model antibody-antigen interactions with precision. Its use of context, including antigen sequences and structural data, enables it to outperform traditional models like ProteinMPNN.
6. Applications of IgDesign span therapeutic antibody development, including engineering antibodies with enhanced binding, reducing discovery timelines, and optimizing candidates for drug pipelines.
7. By releasing its code and datasets, IgDesign fosters open innovation in antibody engineering. The model sets a new standard for community benchmarks and invites collaboration to improve computational antibody design.
8. Code and SPR datasets(>1000 labeled SPR data points) under MIT License.
@CMStegmann @joshim5 @amirshanehsaz
💻Code: github.com/AbSciBio/igdesign
📜Paper: biorxiv.org/content/10.1101/…
#DeepLearning #AntibodyDesign #ComputationalBiology #DrugDiscovery #ProteinEngineering
Christian Stegmann retweeted
Biologic drug discovery with AI. Listen to Sean McClain, founder & CEO of Absci @abscibio, on The Long Run. timmermanreport.com/2024/07/…
Christian Stegmann retweeted
"The average R&D efficiency of big pharma was $6.16 billion total R&D expenditures per new drug." 😱 And remember, that's the average, meaning ~half are higher than that! @ideapharma $XBI sciencedirect.com/science/ar…
Christian Stegmann retweeted
We are delighted to welcome Prof Sir Mene Pangalos to our Board of Directors and as Co-Chair of our Scientific Advisory Board. Mene brings a wealth of experience from his distinguished career, most recently as EVP of BioPharmaceuticals R&D at AstraZeneca. investors.absci.com/news-rel…
Christian Stegmann retweeted
We’re back again, this time with details on our models for de novo design and new, open sourced data on functionality and developability, going beyond binding. We show one design has 3x higher potency than trastuzumab!
Paper: biorxiv.org/content/10.1101/…
Data: github.com/AbSciBio/unlockin…
Christian Stegmann retweeted
We are pleased to announce that Absci will be unveiling encouraging pre-clinical findings on our novel anti-TL1A antibody program, ABS-101, at the J.P. Morgan Healthcare Conference this week. Watch the presentation live Thur. at 10:30AM PT or on demand at investors.absci.com
Christian Stegmann retweeted
We’re excited to announce our new strategic partnership with @precisionlifeAI. Under the partnership, we’ll be working together to discover and develop a shared pipeline of biotherapeutics for up to five mutually agreed-upon targets and indications. investors.absci.com/news-rel…
Christian Stegmann retweeted
We @abscibio are excited to unveil IgDesign™ @NeurIPSConf and present our work at @workshopmlsb @AI4D3 @genbio_workshop! IgDesign is an antibody inverse folding model that we have experimentally validated in our lab. Read the paper here: biorxiv.org/content/10.1101/… #NeurIPS2023
Christian Stegmann retweeted
Out now, our latest work on mapping the cardiovascular system at single cell resolution: biorxiv.org/content/10.1101/…
Led by the incredibly talented trio of Alessandro Arduini, Stephen Fleming & @LingXiao_PhD from our teams @broadinstitute, @BayerPharma, @mghcvrc & @MGHHeartHealth.
Christian Stegmann retweeted
We are excited to announce our new collaboration with Almirall! We’ll be working together to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. investors.absci.com/news-rel…
Christian Stegmann retweeted
At R&D Day this week, we unveiled our internal drug pipeline, recent technical and business milestones, and a peek into the future of AI drug creation. Check out our latest blog to learn more about some of the highlights: absci.com/rd-day-2023/
Christian Stegmann retweeted
David Hampton planted douglas fir and larch trees in a forest in Oregon to resemble a face. Every autumn the larch pines turn orange and the smiley face stands out
The face is about 300 feet in diameter.
rope was used to measure the circle douglas fir was planted for the eyes and mouth and the rest of the face was filled out with larch. both species will eventually be harvested but will smile at least for the next 30-50 years
Christian Stegmann retweeted
GOLDEN. 🥇
congratulations to Daniel Theis and Germany for winning their first-ever @FIBAWC gold medal.
Christian Stegmann retweeted
On this day, in 2003: the moment Germany realised that it is, really, the sick man of Europe.
Rudi Völler, coach of the national football team, with a legendary rant (after a goalless draw against Iceland) on Germans' delusion of grandeur. youtube.com/watch?v=vZ4nYRdP…
Christian Stegmann retweeted
Is having even more gene-disease associations still useful for picking drug targets?
For which types of programs does it matter?
Has pharma shifted focus towards genetically validated targets?
New paper by me, @mnelsonxy, @DongCoco90417, & @jivecast doi.org/10.1101/2023.06.23.2…👇































